Network pharmacology and in-vitro study demonstrates that quercetin inhibits joint inflammation and synoviocyte proliferation, suggesting multi-target therapeutic potential in rheumatoid arthritis.
AbstractBackground: Rheumatoid arthritis (RA) is a prevalent autoimmune disorder that causeschronic inflammation, stiffness, and progressive destruction of synovial joints. TraditionalAyurvedic formulations contain multi-target phytoconstituents that can modulate complexinflammatory pathways. Network pharmacology provides a holistic, systems-based approachto understanding these synergistic therapeutic mechanisms.Objective: This study aims to elucidate the multi-target therapeutic mechanisms of quercetin,a prominent Ayurvedic phytoconstituent, against RA by integrating network pharmacology,molecular docking, and in-vitro experimental validation.Methodology: Quercetin’s pharmacokinetic properties and targets were retrieved usingTCMSP and SwissTargetPrediction. RA-related genes were collected from GeneCards,OMIM, and DisGeNET. Protein-protein interaction (PPI) networks were constructed viaSTRING and Cytoscape, followed by GO and KEGG enrichment analyses. Binding affinitieswere simulated using molecular docking. Finally, in-vitro validation was conducted usingTNF-α-induced Rheumatoid Arthritis Fibroblast-Like Synoviocytes (RAFLS), evaluatedthrough MTT assays, ELISA, RT-PCR, Western blotting, and flow cytometry.Results: Network analysis revealed 58 intersecting therapeutic targets, with TNF, IL6, AKT1,and MAPK1 identified as central hub genes. KEGG analysis demonstrated significantenrichment in TNF and NF-κBsignaling pathways. Molecular docking showed strong bindingenergies, notably with COX-2 (-9.0 kcal/mol) and TNF-α (-8.7 kcal/mol). In-vitroexperiments confirmed that quercetin dose-dependently reduced abnormal RAFLSproliferation, significantly suppressed inflammatory cytokines (IL-1β, IL-6, TNF-α),downregulated NF-κB and MAPK protein expression, reduced oxidative stress, and promotedcellular apoptosis.Conclusion: Quercetin demonstrates significant potential as a multi-target therapeutic agentfor rheumatoid arthritis. By integrating computational predictions with in-vitro validation, thestudy concludes that quercetin effectively mitigates disease progression by synergisticallymodulating key inflammatory pathways, suppressing cytokine production, and reducingabnormal cellular proliferation and oxidative stress.
No takes yet. Share an insight, caveat, or question.
Miss Priynaka Jain, Dr.Bindu Amit.U., Dr.Nagnath Ramrao kadam, Mrs. Mande S.V. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: